Corient Private Wealth
OCUL icon

Corient Private Wealth’s Ocular Therapeutix OCUL Stock Holding History

Corient Private Wealth’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Buy
49,629
+20,187
+69% +$183K ﹤0.01% 2242
2026
Q1 		$249K Sell
29,442
-773
-3% -$7.37K ﹤0.01% 2428
2025
Q4 		$367K Sell
30,215
-200
-0.7% -$2.43K ﹤0.01% 2039
2025
Q3 		$356K Buy
+30,415
New +$364K ﹤0.01% 2010

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Corient Private Wealth's OCUL Position: Q2 2026 in Review

Corient Private Wealth increased its Ocular Therapeutix (OCUL) stake by 69% in Q2 2026, buying an estimated $183K and bringing the position to 49,629 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #2242.

Corient Private Wealth first reported a position in OCUL in Q3 2025 and has held it in 4 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Corient Private Wealth held 49,629 shares of Ocular Therapeutix worth $487K as of Q2 2026.
  • Corient Private Wealth bought 20,187 Ocular Therapeutix shares in Q2 2026, an estimated $183K.
  • Ocular Therapeutix made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2242 holding.
  • Corient Private Wealth first reported a position in Ocular Therapeutix in Q3 2025 and has held it in 4 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.